GlobeNewswire Inc | Nov 15, 2021 04:03PM EST

November 15, 2021

FORT COLLINS, Co., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today reported important corporate events and financial results for the third quarter ended September 30, 2021. Statera Biopharma was formerly known as Cleveland BioLabs, Inc. and merged with Cytocom Inc. onJuly 27, 2021.

"We are pleased with our operational progress to integrate the portfolio and advance our clinical programs as we prepare to initiate several clinical trials during 2022, including a pivotal Phase 3 trial for our lead drug candidate, STAT-201, in pediatric Crohns disease, as well as studies of the TLR5 agonist Entolimod as a treatment for anemia and neutropenia in cancer patients, broaden the STAT-205 program to post-acute COVID-19 and study STAT-401 in pancreatic cancer, said Michael K. Handley, Chief Executive Officer of Statera Biopharma. We also expect to further strengthen our cash position to support funding the continued advancement of the Companys clinical-stage pipeline and drive Statera Biopharma toward multiple value infection points. We may also raise additional funding to capitalize on what we believe are myriad internal and external opportunities in the field of immune modulation and bring hope to patients and their families.

Recent Business and Corporate Highlights:

-- Statera Biopharma, Inc. changed its corporate name from Cytocom, Inc. on September 1, 2021, and ticker symbol for common stock was updated from CBLI to STAB. Merger created a company with one of the largest platforms of toll-like immune receptor (TLR) agonists in the biopharmaceutical industry. The expanded pipeline includes TLR4, TLR8 and TLR9 molecules, and the TLR5 agonists, Entolimod and GP532.

-- Statera Biopharma continues to advance its clinical- and development-stage pipeline. Enrollment is expected to begin by the end of 2021 at Loma Linda University Health for Phase 1 pilot study evaluating STAT-205 as a treatment to mitigate progression of SARS-CoV-2, the virus that causes COVID-19.End-of-Phase 2 meeting completed July 2021 for STAT-201 in pediatric Crohns disease; Site selection and set up proceeding infourth quarter of 2021 and Pivotal Phase 3 trial expected to begin enrollment in the first quarter of 2022.Clinical trials for STAT-401 in pancreatic cancer and STAT-600 (Entolimod) in hematologic indications expected in 2022.

-- Utilized a portion of capital commitments for debt and equity financing secured prior to the merger to fund growth initiatives and advance internal pipeline. Utilized $7.7 million of the debt facility in the third quarter.Statera has additional funding capacity under these facilities,which will provide the Company with working capital to continue pipeline development.The Company expects to close further funding commitments by year end.

-- Harnessing scientific capabilities and new research alliances to advance discovery and development of second-generation pipeline assets Screening of new immune compounds underway; using tools and capabilities of its subsidiary ImQuest Life Sciences to determine which compounds are likely to succeed in preclinical and clinical trials.Research alliance with La Jolla Institute for Immunology has Statera Biopharma funding four laboratories and selected research projects that will use Stateras platform technologies to discover new immune-modulating agents targeting toll-like immune receptors to address cancer, autoimmune conditions,and infectious diseases.

Financial Results

-- Form 10-Q filed today is first opportunity for Statera Biopharma to present consolidated financial reports covering the results of Cytocom, Cleveland BioLabs, and ImQuest combined. -- Under GAAP applicable to the mergers, the financial presentation covers: Income statement for the merged companies only from their respective merger dates;Statements of Assets and Liabilities in the balance sheets only from their respective merger dates;The Income statements and statements of Assets and Liabilities for periods prior to June 24, 2021 cover old Cytocom only;Statements of Equity for all periods cover old Cleveland BioLabs and old Cytocom from a legal and accounting survivor, respectively, as a result of the merger.

-- Highlights of the three three-month period ended September 30, 2021 were: Revenues of $0.24 million from research services provided by the ImQuest subsidiary to its customers. Cost of revenues was $0.12 million, resulting in a gross profit of $0.12 million. No revenues or expenses are included in the period for old Cytocom or old Cleveland BioLabs. There were no revenues in the same period in 2020.A net loss of $12.7 million, or ($0.47) per share, compared to a net loss of $5.7 million, or ($1.84) per share for the same period in 2020.R&D expenses decreased from $4.38 million for the three months ended September 30, 2020 to $3.43million for the three months ended September 30, 2021, a 21.6% decrease. The decrease is primarily attributable to a $3.8million decrease in one-time patent expenses for the three months ended September 30, 2020 related to the transfer of intellectual property to the Company by Immune Therapeutics, Inc., partially offset by a $1.6 million increase in expenses associated with STAT-201: Crohn's disease, $0.4 million increase in expenses associated with STAT-401: Pancreatic cancer, and $1.0 million increase in non-program specific expenses.G&A expenses increased from $1.8million for the three months ended September 30, 2020to $6.3 million for the three months endedSeptember 30, 2021, an increase of 252.8%. This increase is primarily related to a $2.6 million increase in payroll expenses of which $1.9 million was for stock-based compensation, a $0.6 million increase in stock listing expenses, a $0.2 million increase in professional fees, and a $1.1 million increase in consultants, insurance, and other general expenses.In the nine months ended September 30, 2021, the Company used $20.1 million of cash in operating activities. It funded these operations with: $13.6 million provided by investing activities, primarily from the net assets acquired in the merger with Cleveland BioLabs;$20.1 million provided by financing activities, in particular net proceeds of $14.7 million from a $15.0 million note issued to Avenue Ventures and $5.7 million due to the issuance of common stock, partially offset by repayments in notes payable and payment of debt issuance costs of $0.4 million.At September 30, 2021, Statera BioPharma reported cash, cash equivalents, and restricted cash of $14.4 million, an increase of $13.8 million over the $0.6 million reported at the end of 2020.

Conference Call & Audio Webcast DetailsStatera Biopharma, Inc. will host a conference call and live audio webcast on Monday, November 15, 2021, at 5:30 p.m. ET, to discuss its corporate and financial results for the third quarter 2021.

Telephone Access: U.S. and Canada 800-937-6813Telephone Access: International 213-660-0853Access CodeforAll Callers 2973387Live Audio Webcast https://edge.media-server.com/mmc/p/ bht979a3

An audio webcast will be accessible via the Investors section of the Companys website https://www.staterabiopharma.com/investors. An archive of the webcast will remain available for 90 days beginning at approximately 6:30 p.m. ET, on November 15, 2021.

About Statera BiopharmaStatera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptors (TLR) in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that plays a key role in the innate immune system. Statera is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Statera has clinical programs for Crohns disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis. To learn more about Statera Biopharma, please visit https://www.staterabiopharma.com/.

Forward Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties. All statements other than statements of current or historical fact contained in this press release, including statements regarding the Company's expected clinical development timeline for the Company's product candidates, future financial position, business strategy, new products, budgets, liquidity, cash flows, projected costs, regulatory approvals, the impact of any laws or regulations applicable to the company, and plans and objectives of management for future operations, are forward-looking statements. The words "anticipate," "believe," "continue," "should," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company based these forward-looking statements on the current expectations about future events held by management. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond the Company's control. The company's actual future results may differ materially from those discussed here for various reasons. The Company discusses many of these risks under the heading "Risk Factors" in the proxy statement/prospectus filed with the SEC on June 10, 2021, as updated by the company's other filings with the SEC. Factors that may cause such differences include, but are not limited to, the outcome of any legal proceedings that have been or may be instituted against the company related to the merger between Cleveland BioLabs and Cytocom; unexpected costs, charges or expenses resulting from the merger; the Company's need for additional financing to meet the Company's business objectives; the Company's history of operating losses; the Company's ability to successfully develop, obtain regulatory approval for, and commercialize the Company's products in a timely manner; the Company's plans to research, develop and commercialize the Company's product candidates; the Company's ability to attract collaborators with development, regulatory and commercialization expertise; the Company's plans and expectations with respect to future clinical trials and commercial scale-up activities; the Company's reliance on third-party manufacturers of the Company's product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to serve those markets; the rate and degree of market acceptance of the Company's product candidates; regulatory requirements and developments in the United States, the European Union and foreign countries; the performance of the Company's third-party suppliers and manufacturers; the success of competing therapies that are or may become available; the Company's ability to attract and retain key scientific or management personnel; the Company's historical reliance on government funding for a significant portion of the Company's operating costs and expenses; government contracting processes and requirements; the exercise of significant influence over the Company's company by the Company's largest individual stockholder; the impact of the novel coronavirus ("COVID-19") pandemic on the Company's business, operations and clinical development; the geopolitical relationship between the United States and the Russian Federation as well as general business, legal, financial and other conditions within the Russian Federation; the Company's ability to obtain and maintain intellectual property protection for the Company's product candidates; the Company's potential vulnerability to cybersecurity breaches; and other factors discussed in the Company's SEC filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and the risk factors discussed under the heading "Risk Factors" in the proxy statement/prospectus the company filed in connection with the merger on June 10, 2021. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.

- Financial Statements to Follow

STATERA BIOPHARMA, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED)

September 30, December 31, 2021 2020 ASSETS Current assets: Cash and cash equivalents $ 9,216,349 $ 593,869 Short-term investments 233,642 ? Accounts receivable 144,244 ? Due from subsidiary ? 329,330 Prepaid expenses 2,688,472 ? Other current assets 1,045,332 2,547 Total current assets 13,328,039 925,746 Non-current assets: Operating lease right-of-use assets 840,590 101,048 Restricted cash 5,000,000 ? Goodwill 76,972,668 ? Intangible assets, net 1,575,278 ? Property and equipment, net 119,133 8,690 Contract asset 192,222 ? Total non-current assets 84,699,891 109,738 Assets of discontinued operation 8,123 Total assets $ 98,036,053 $ 1,035,484 LIABILITIES AND STOCKHOLDERS? EQUITY Current liabilities: Accounts payable and accrued expenses $ 5,928,805 $ 2,687,847 Current portion of operating lease 198,302 30,758 liabilitiesDeferred revenue 506,032 ? Stock issuances due 470,828 ? Notes payable 2,883,333 1,902,237 Advances from related party 200,000 ? Total current liabilities 10,187,300 4,620,842 Operating lease liabilities, net of current 737,403 70,380 portionLong-term debt 12,916,667 ? Total long-term liabilities 13,654,070 70,380 Liabilities of discontinued operation 63 ? Total liabilities 23,841,433 4,691,222 Stockholders? equity (deficit): Preferred stock, $.005 par value; 1,000,000shares authorized as of September 30, 2021and December 31, 2020; 0 shares issued and ? ? outstanding as of September 30, 2021 andDecember 31, 2020Common stock, $.005 par value; 150,000,000shares authorized as of September 30, 2021and 25,000,000 shares authorized as ofDecember 31, 2020; 32,095,520 shares issued 160,478 160,478 and outstanding as of September 30, 2021and 13,376,062 shares issued andoutstanding as of December 31, 2020Additional paid-in capital 126,220,319 23,946,747 Accumulated other comprehensive loss (2,014 ) ? Accumulated deficit (52,256,361 ) (27,762,963 )Total Statera Biopharma, Inc. stockholders? 74,122,422 (3,655,738 )equity (deficit)Noncontrolling interest in stockholders? 72,198 ? equityTotal stockholders? equity (deficit) 74,194,620 (3,655,738 )Total liabilities and stockholders? equity $ 98,036,053 $ 1,035,484

See Notes to Condensed Consolidated Financial Statements.December 31, 2020 capital structure is not retroactively restated for the recapitalization as a result of the merger.

STATERA BIOPHARMA, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)

For the Three Months Ended For the Nine Months Ended September 30, September 30, 2021 2020 2021 2020Revenues: Grants and $ 236,519 $ - $ 236,519 $ - contractsCost of Revenue:Cost of goods 115,927 - 115,927 - soldGross Profit 120,592 - 120,592 - Operating expenses:Research and 3,434,977 4,383,325 6,274,936 4,509,890 developmentSales andmarketing 23,242 - 26,037 - expenseGeneral and 6,306,323 1,787,333 14,981,086 2,284,577 administrativeTotaloperating 9,764,542 6,170,658 21,282,059 6,794,467 expensesLoss from (9,643,950 ) (6,170,658 ) (21,161,467 ) (6,794,467 )operationsOther income (expense):Interest andother income (3,089,301 ) 491,817 (3,463,572 ) (1,069,403 )(expense)Total otherincome (3,089,301 ) 491,817 (3,463,572 ) (1,069,403 )(expense)Income fromdiscontinuedoperations, (1 ) - (1 ) - net of incometaxesNet loss (12,733,250 ) (5,678,841 ) (24,625,038 ) (7,863,870 )Net lossattributableto 13,419 - 13,419 - noncontrollinginterestsNet lossattributableto Statera $ (12,719,831 ) $ (5,678,841 ) $ (24,611,619 ) $ (7,863,870 )Biopharma,Inc.Net lossattributableto commonstockholders $ (0.47 ) $ (1.84 ) $ (0.86 ) $ (1.13 )per share ofcommon stock,basic anddilutedWeightedaverage numberof shares usedin calculating 27,036,583 3,081,294 28,671,422 6,957,095 net loss pershare, basicand diluted

See Notes to Condensed Consolidated Financial Statements.

STATERA BIOPHARMA, INC. AND SUBSIDIARIESSUMMARIZED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)

For the Nine Months Ended September 30, 2021 2020 Variance Cash flows usedin operating $ (20,064,262 ) $ (8,363,019 ) $ (11,701,243 )activitiesCash flowsprovided by (used 13,559,901 (6,613 ) 13,566,514 in) investingactivitiesCash flowsprovided by 20,128,855 8,688,090 11,440,765 financingactivitiesEffect ofexchange rate on (2,014 ) - (2,014 )cash and cashequivalentsIncrease in cashand cash 13,622,480 318,458 13,304,022 equivalentsCash and cashequivalents at 593,869 1,650 592,219 beginning ofperiodCash, restrictedcash and cash $ 14,216,349 $ 320,108 $ 13,896,241 equivalents atend of period

Contacts:Statera BiopharmaNichol OchsnerExecutive V.P. Investor Relations and Corporate Communications(732) 754-2545nichol.ochsner@staterabiopharma.com Tiberend Strategic Advisors, Inc. Maureen McEnroe, CFA (Investors)(212) 375-2664mmcenroe@tiberend.com

Johanna Bennett (Media)(212) 375-2686Jbennett@tiberend.com